Institutional investors are Roivant Sciences Ltd.'s (NASDAQ:ROIV) biggest bettors and were rewarded after last week's US$290m market cap gain [Yahoo! Finance]
Roivant Sciences Ltd. (ROIV)
Company Research
Source: Yahoo! Finance
A total of 7 investors have a majority stake in the company with 52% ownership 21% of Roivant Sciences is held by insiders If you want to know who really controls Roivant Sciences Ltd. ( NASDAQ:ROIV ), then you'll have to look at the makeup of its share registry. With 37% stake, institutions possess the maximum shares in the company. Put another way, the group faces the maximum upside potential (or downside risk). And as as result, institutional investors reaped the most rewards after the company's stock price gained 3.3% last week. The one-year return on investment is currently 32% and last week's gain would have been more than welcomed. Let's delve deeper into each type of owner of Roivant Sciences, beginning with the chart below. Check out our latest analysis for Roivant Sciences What Does The Institutional Ownership Tell Us About Roivant Sciences? Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generall
Show less
Read more
Impact Snapshot
Event Time:
ROIV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ROIV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ROIV alerts
High impacting Roivant Sciences Ltd. news events
Weekly update
A roundup of the hottest topics
ROIV
News
- Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024GlobeNewswire
- Dermavant Announces FDA Acceptance of Supplemental New Drug Application (sNDA) for VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older [Yahoo! Finance]Yahoo! Finance
- Roivant and Kinevant Sciences Complete Enrollment in RESOLVE-Lung, a Phase 2 Study Evaluating Namilumab for Chronic Pulmonary SarcoidosisBusiness Wire
- Roivant Sciences: Cashing In On Vants And Ventures [Seeking Alpha]Seeking Alpha
- OSR Holdings and SillaJen have entered into a Memorandum of Understanding to collaboratively pursue the development of innovative therapeutics and enter the U.S. market [Yahoo! Finance]Yahoo! Finance
ROIV
Earnings
- 2/13/24 - Beat
ROIV
Sec Filings
- 4/30/24 - Form 4
- 4/26/24 - Form 4
- 4/26/24 - Form 4
- ROIV's page on the SEC website